AARD vs HCHL โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
AARD Captures Institutional Edge (2โ1 Pillars ยท 5โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Aardvark Therapeutics, Inc. Common Stock (AARD) driven by superior Growth & Margin, Options & Structure while HCHL counters with relative strength in Momentum & Technical. Fundamentally, AARD trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus HCHL at N/M Forward P/E and -101.6% operating margin (-45.7% YoY). In options structure, AARD sits in UNCLASSIFIED (26th %ile IV; Dealer Gamma Walls on Pro) against HCHL sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | AARD | HCHL | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $19.9M | $120.0M | Larger Scale | HCHL |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | -45.7% | Higher Growth | AARD |
| Operating Margin (TTM) Profitability | 0.0% | -101.6% | Higher Margin | AARD |
| Net Profit Margin Profitability | 0.0% | -35.7% | Higher Margin | AARD |
| Return on Equity (ROE) Capital Efficiency | -66.0% | -173.0% | Higher ROE | AARD |
| 52-Week Range Position Momentum | 1% ($1โ$17) | 49% ($1โ$7) | Stronger Trend | HCHL |
| Beta / 30D Volatility Risk Regime | 4.01ฮฒ ยท 285% Vol | -0.84ฮฒ ยท 94% Vol | Lower Realized Risk | HCHL |
| Unified Institutional Score Composite Signal | 46.4 / 100 (HOLD) | 45.1 / 100 (HOLD) | Higher Composite | AARD |